Corneal Endothelial Dysfunction

2

Review clinical trials related to Corneal Endothelial Dysfunction. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

The purpose of this study is to assess the efficacy and safety of single injection dose of AURN001 compared with placebo in adult participants with corneal edema secondary to corneal endothelial dysfunction.

Participants needed: 120
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Aurion BiotechUpdated: May 22, 2026Locations: 12
Eligibility criteria

Have corneal edema secondary to corneal endothelial dysfunction, requiring surge... [+2]

Have progressive corneal dystrophies or degenerations [+1]

Status: Recruiting

PVEK Corneal Implant For Treatment of Corneal Edema

The goal of this clinical trial is to learn if PVEK, a corneal implant , is safe and well tolerated for people with corneal swelling caused by Fuchs' endothelial dystrophy or pseudophakic bullous keratopathy who need endothelial keratoplasty. The main questions it aims to answer are: What side effects may happen after the PVEK implant? How many participants can complete the first 6 months after surgery without needing another treatment because the implant did not help enough or was not tolerable? This is a Phase 1 (first-in-human) study with one study group, meaning all participants receive the PVEK implant (there is no placebo or comparison group). About 15 participants will take part and will be followed for up to 12 months after surgery. Participants will: Complete screening tests (including eye exams and routine health checks) Have the PVEK implantation surgery Use prescribed eye drops after surgery Return for follow-up visits over the next 12 months for eye exams and tests (such as vision testing, eye pressure checks, and eye scans)

Participants needed: 15
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Precise BioUpdated: Jan 12, 2026Locations: 3
Eligibility criteria

Not listed